Modifies hospital reimbursement for biological products used in cell or gene therapy for rare diseases.

The bill amends Minnesota Statutes to allow the commissioner to provide separate reimbursement to hospitals for biological products used in cell or gene therapy to treat rare diseases. This applies if the drug manufacturer enters into a value-based arrangement with the commissioner. The reimbursement rate is based on the methodology used for drugs administered in an outpatient setting. Hospitals must be paid the actual acquisition cost for these biological products.

Modifies hospital reimbursement for biological products used in cell or gene therapy for rare diseases.

The bill amends Minnesota Statutes to allow the commissioner to provide separate reimbursement to hospitals for biological products used in cell or gene therapy to treat rare diseases. This applies if the drug manufacturer enters into a value-based arrangement with the commissioner. The reimbursement rate is based on the methodology used for drugs administered in an outpatient setting. Hospitals must be paid the actual acquisition cost for these biological products.